Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

29/03/2016 - 3 minutes

Bone Therapeutics (Belgium) has released its financial results for 2015, which show a solid cash position and promising results in treating Bone conditions in ongoing clinical trials.

bone_therapeutics_allob_preob_cell_therapyThis Belgian Biotech is developing cell therapies to treat a bone diseases like osteoporosis with considerable success so far – and 2015 was a year with plenty of important milestones.

These included significant progress in the several clinical trials that Bone Therapeutics is conducting.

ALLOB is an allogeneic cell therapy which has shown a good safety profile. Bone therapeutics has now treated 12 patients (of the expected 18) in its phase IIa trial for spinal fusion, and the therapy was already successful in at least one of the patients.

On the other hand, PREOB (the autologous version of the therapy) is also showing promising results – which could make it a breakthrough therapy for severe osteoporosis.

The safety and cell migration of PREOB is being studied in a phase IIa trial with osteoporosis patients,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member